Bris­tol My­ers Squibb gets re­view date for Op­di­vo com­bo in gas­tric can­cer, look­ing to over­turn Keytru­da's 3-year lead

The past two months have been tough for Bris­tol My­ers Squibb and its check­point in­hibitor Op­di­vo af­ter set­backs in lung and brain can­cers. But in the bat­tle against Mer­ck’s Keytru­da, any suc­cess mat­ters — and now Bris­tol could be look­ing at a quick ap­proval for Op­di­vo in an un­matched in­di­ca­tion.

The FDA will launch a speedy re­view of a com­bi­na­tion of Bris­tol My­ers Squibb’s Op­di­vo and chemother­a­py to treat first-line pa­tients with ad­vanced or metasta­t­ic gas­tric can­cer, gas­troe­sophageal junc­tion can­cer or esophageal ade­no­car­ci­no­ma, the drug­mak­er said Wednes­day. The agency set an ac­tion date of May 25 for the ap­pli­ca­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER